PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 154 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is 1.56 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $150,000 | -11.8% | 18,678 | -17.9% | 0.05% | +17.1% |
| Q1 2018 | $170,000 | +70.0% | 22,749 | +35.8% | 0.04% | +41.4% |
| Q4 2017 | $100,000 | -70.1% | 16,750 | -66.0% | 0.03% | -75.0% |
| Q2 2017 | $335,000 | +82.1% | 49,300 | +152.4% | 0.12% | +54.7% |
| Q1 2017 | $184,000 | +78.6% | 19,532 | +64.1% | 0.08% | +38.9% |
| Q4 2016 | $103,000 | – | 11,900 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
| Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
| BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
| Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
| TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
| SEARLE & CO. | 60,000 | $349,000 | 0.34% |
| TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
| RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
| Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
| TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |